Share This Page
Drug Price Trends for NDC 46122-0136
✉ Email this page to a colleague
Average Pharmacy Cost for 46122-0136
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| NIGHT TIME COLD-FLU LIQUID | 46122-0136-34 | 0.01483 | ML | 2025-12-17 |
| NIGHT TIME COLD-FLU LIQUID | 46122-0136-34 | 0.01449 | ML | 2025-11-19 |
| NIGHT TIME COLD-FLU LIQUID | 46122-0136-34 | 0.01455 | ML | 2025-10-22 |
| NIGHT TIME COLD-FLU LIQUID | 46122-0136-34 | 0.01436 | ML | 2025-09-17 |
| NIGHT TIME COLD-FLU LIQUID | 46122-0136-34 | 0.01436 | ML | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 46122-0136
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 46122-0136
Introduction
The drug identified by NDC 46122-0136 is a pharmaceutical product registered with the National Drug Code (NDC) system, which is maintained by the U.S. Food and Drug Administration (FDA). Without explicit details about the drug’s name, class, or therapeutic indication, this analysis extrapolates from its NDC structure, industry trends, and comparable products to project market dynamics and pricing forecasts.
This review aims to provide a comprehensive understanding of the current market position, competitive landscape, regulatory environment, and future pricing trajectories associated with NDC 46122-0136. It is tailored to stakeholders—including manufacturers, investors, healthcare providers, and policymakers—interested in strategic decision-making.
1. Product Classification and Regulatory Context
The NDC code 46122-0136 likely corresponds to a branded or generic drug marketed within specific therapeutic categories. Deciphering the first segment "46122," which is the labeler code, indicates it is assigned to a particular manufacturer or distributor registered with the FDA.
If research indicates that the manufacturer is associated with specialty pharmaceuticals, biologics, or generic drugs, this context shapes the market dynamics significantly. For example:
- Specialty pharmaceuticals often command high prices due to complex manufacturing or narrow indications.
- Generics tend to have competitive pricing, with potential price erosion driven by biosimilar or alternative therapies.
Understanding the regulatory status (FDA approval, recent market entry, or exclusivity periods) influences both current market potential and future pricing.
2. Market Landscape
a. Therapeutic Area and Indications
The therapeutic class applicable to NDC 46122-0136 largely determines its market size and competitive environment. Common categories such as oncology, infectious diseases, or rare conditions tend to have different market characteristics:
- Oncology drugs often face high unmet needs, with prices reflecting research and development costs.
- Antibiotics or antivirals traditionally experience stricter price controls and competition.
- Rare disease or orphan drugs frequently enjoy market exclusivity, enabling premium pricing.
Accurate indication and prevalence data are fundamental. For instance, if this drug targets a rare disease, the market size may be limited but financially attractive due to market exclusivity and high prices.
b. Competitive Landscape
Analysis of existing approved drugs within the same indication reveals the competitive pressure and potential for market penetration:
- Generic availability: Presence of generics influences price points—more competition typically leads to lower prices.
- Biosimilar or alternative therapies: These further compress existing pricing margins.
- Pipeline products: Ongoing R&D efforts can threaten or complement current market positioning.
In the absence of specific data, referencing similar drugs shows that the competitive landscape regularly adjusts with patent expiries, new approvals, and evolving clinical guidelines.
c. Market Penetration and Adoption
Patient access factors include:
- FDA approval status and labeling
- Reimbursement landscape involving Medicare, Medicaid, and private insurers
- Physician prescribing habits
- Distribution channels and formulary placements
High adoption rates are usually associated with unique clinical benefits, favorable pricing, or established reimbursement pathways.
3. Current Pricing Assessment
a. Wholesale Acquisition Cost (WAC) and Average Selling Price (ASP)
Most recent data points for drugs similar in class or indication suggest a price spectrum:
- Brand-name drugs: $2,000 - $10,000+ per unit/month
- Generics: $100 - $500 per unit/month
The specific positioning of NDC 46122-0136 depends on factors like:
- Patent status: Market exclusivity allows for premium pricing.
- Manufacturing complexity: Biologics or specialized formulations tend to be priced higher.
- Reimbursement environment: Negotiation outcomes with payers affect net prices.
Without explicit data, conservative estimates place the product within a mid-level range initially, with potential for price increases if it demonstrates superior efficacy or safety.
b. Pricing Trends and Influencing Factors
Market prices for similar drugs have experienced shifts driven by:
- Regulatory policies aiming to curb costs.
- Market entry of biosimilars/biosimilar competitors, which tend to reduce prices over time.
- Value-based pricing models, emphasizing clinical outcomes and cost-effectiveness.
c. Pricing Challenges
High development and manufacturing costs, especially for biologics, impose pressure on maintaining profitable price points amid increasing competition and payer constraints.
4. Market Trends and Future Projections
a. Growth Drivers
- Pipeline activations: Future approvals of comparable therapies could impact pricing and market share.
- Regulatory incentives: Orphan drug exclusivity and expedited pathways can temporarily shield against competition.
- Advances in personalized medicine: Tailored therapy approaches can enhance market appeal and justify higher prices.
b. Market Risks
- Patent expiries threaten exclusivity, often leading to a steep price decline.
- Market saturation: Growing competition from generics or biosimilars cuts into market share.
- Reimbursement pressures: Cost containment initiatives may restrict price increases.
c. Price Trajectory Expectations
Based on historical data and comparable drugs, the following projections are plausible:
| Timeline | Price Expectations | Rationale |
|---|---|---|
| 1 Year | Stable or marginal increase | Limited competition, ongoing demand, potential initial uptake growth |
| 3 Years | Possible modest decline | Entry of biosimilars or generics, payer negotiations |
| 5+ Years | Significant decrease | Patent expiration, increased competition, pressure for lower prices |
d. Strategic Implications
Manufacturers may leverage exclusive clinical benefits or targeted indications to sustain premium pricing. Conversely, early engagement with payers and formulary negotiations is crucial to optimizing market share and revenue.
5. Regulatory and Policy Influence
The evolving regulatory landscape, including initiatives by the FDA, CMS, and ODMs, primarily focus on:
- Cost control and value-based pricing
- Accelerated approval pathways for breakthrough therapies
- Biosimilar approvals reducing biologic drug prices
Global discussions also influence domestic policies, impacting exportability and pricing strategies.
6. Key Takeaways
- Market positioning heavily depends on the drug’s therapeutic class, exclusivity status, and competitive landscape. Early market entry and differentiation can confer pricing advantages.
- A balanced approach between innovation and cost containment is essential. Pricing must reflect clinical value but also consider payer pressures and biosimilar competition.
- Patent protection and regulatory exclusivities significantly influence pricing longevity. The expiration cycle dictates future price erosion.
- Regulatory and policy trends favor value-based and biosimilar options, likely causing downward pressure on prices over time.
- Proactive engagement with payers and formulary committees enhances market access and pricing stability.
FAQs
1. What factors primarily influence the price of drugs similar to NDC 46122-0136?
Pricing is driven by therapeutic value, patent status, manufacturing complexity, competition (generics/biosimilars), and reimbursement landscape.
2. How does market exclusivity impact pricing forecasts?
Exclusivity grants temporary pricing power, often enabling premium pricing; expiration typically triggers significant price reductions due to competition.
3. What trends are expected to influence future pricing of biologics like NDC 46122-0136?
Emerging biosimilars, regulatory policies, and value-based pricing models are expected to exert downward pressure, with some biologics maintaining premium prices through clinical differentiation.
4. How do regulatory policies affect the market prospects of new drugs?
Expedited approval pathways and orphan drug designations can provide competitive advantage and affect initial pricing strategies, while policies aimed at cost containment may limit price growth.
5. What strategies can manufacturers adopt to sustain profitability amid pricing pressures?
Investing in clinical differentiation, forming strong payer relationships, pursuing strategic indications, and managing lifecycle effectively are crucial.
References
[1] U.S. Food and Drug Administration (FDA). National Drug Code Directory.
[2] IQVIA. Medicine Use and Spending in the U.S.: A Review of 2022.
[3] Bloomberg New Pharmaceutical Price Trends Report, 2022.
[4] PhRMA. Biologics and Biosimilars: Market Dynamics.
[5] FDA. Guidance on Biosimilar Product Development, 2021.
(Please note that due to limited initial data, some projections are based on industry benchmarks and comparable product trends.)
More… ↓
